Advertisement
Screener

Verastem, Inc. (VSTM) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Verastem, Inc. Operating Cash Flow

Verastem, Inc. (VSTM) reported Operating Cash Flow of -$96.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06

  • Verastem, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$43.91M.
  • Verastem, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$52.12M.
  • Verastem, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$29.95M.
  • Verastem, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$36.22M.
  • Verastem, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$137.51M.
  • Verastem, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$104.77M.
  • Verastem, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$86.46M.
  • Verastem, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$63.67M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$43.91M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$96.03M
10-Q · filed 2026-08-06
-$125.98M
derived: sum of 3 quarters · filed 2026-08-06
-$162.19M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$52.12M
10-Q · filed 2026-05-07
-$82.07M
derived: sum of 2 quarters · filed 2026-05-07
-$118.29M
derived: sum of 3 quarters · filed 2026-05-07
-$150.95M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$29.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
-$66.17M
derived: sum of 2 quarters · filed 2026-03-04
-$98.83M
derived: sum of 3 quarters · filed 2026-08-06
-$137.51M
10-K · filed 2026-03-04
2025-09-30-$36.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$68.88M
derived: sum of 2 quarters · filed 2026-08-06
-$107.56M
10-Q · filed 2025-11-04
-$132.65M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$32.66M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$71.34M
10-Q · filed 2026-08-06
-$96.44M
derived: sum of 3 quarters · filed 2026-08-06
-$120.23M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$38.68M
10-Q · filed 2026-05-07
-$63.77M
derived: sum of 2 quarters · filed 2026-05-07
-$87.57M
derived: sum of 3 quarters · filed 2026-05-07
-$115.14M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$25.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
-$48.89M
derived: sum of 2 quarters · filed 2026-03-04
-$76.46M
derived: sum of 3 quarters · filed 2026-03-04
-$104.77M
10-K · filed 2026-03-04
2024-09-30-$23.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$51.37M
derived: sum of 2 quarters · filed 2025-11-04
-$79.67M
10-Q · filed 2025-11-04
-$109.35M
derived: sum of 4 quarters · filed 2026-03-04
2024-06-30-$27.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$55.88M
10-Q · filed 2025-08-07
-$85.56M
derived: sum of 3 quarters · filed 2026-03-04
-$102.15M
derived: sum of 4 quarters · filed 2026-03-04
2024-03-31-$28.31M
10-Q · filed 2025-05-13
-$57.99M
derived: sum of 2 quarters · filed 2026-03-04
-$74.58M
derived: sum of 3 quarters · filed 2026-03-04
-$94.48M
derived: sum of 4 quarters · filed 2026-03-04
2023-12-31-$29.68M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
-$46.27M
derived: sum of 2 quarters · filed 2026-03-04
-$66.17M
derived: sum of 3 quarters · filed 2026-03-04
-$86.46M
10-K · filed 2026-03-04
2023-09-30-$16.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
-$36.49M
derived: sum of 2 quarters · filed 2024-11-06
-$56.78M
10-Q · filed 2024-11-06
-$73.39M
derived: sum of 4 quarters · filed 2025-03-20
2023-06-30-$19.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$40.19M
10-Q · filed 2024-08-08
-$56.81M
derived: sum of 3 quarters · filed 2025-03-20
-$71.89M
derived: sum of 4 quarters · filed 2025-03-20
2023-03-31-$20.29M
10-Q · filed 2024-05-09
-$36.90M
derived: sum of 2 quarters · filed 2025-03-20
-$51.98M
derived: sum of 3 quarters · filed 2025-03-20
-$64.68M
derived: sum of 4 quarters · filed 2025-03-20
2022-12-31-$16.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
-$31.70M
derived: sum of 2 quarters · filed 2025-03-20
-$44.39M
derived: sum of 3 quarters · filed 2025-03-20
-$63.67M
10-K · filed 2025-03-20
2022-09-30-$15.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
-$27.78M
derived: sum of 2 quarters · filed 2023-11-08
-$47.06M
10-Q · filed 2023-11-08
-$56.99M
derived: sum of 4 quarters · filed 2024-03-14
2022-06-30-$12.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
-$31.98M
10-Q · filed 2023-08-08
-$41.91M
derived: sum of 3 quarters · filed 2024-03-14
-$52.73M
derived: sum of 4 quarters · filed 2024-03-14
2022-03-31-$19.28M
10-Q · filed 2023-05-09
-$29.21M
derived: sum of 2 quarters · filed 2024-03-14
-$40.04M
derived: sum of 3 quarters · filed 2024-03-14
-$53.47M
derived: sum of 4 quarters · filed 2024-03-14
2021-12-31-$9.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
-$20.76M
derived: sum of 2 quarters · filed 2024-03-14
-$34.18M
derived: sum of 3 quarters · filed 2024-03-14
-$53.50M
10-K · filed 2024-03-14
2021-09-30-$10.83M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
-$24.25M
derived: sum of 2 quarters · filed 2022-11-03
-$43.57M
10-Q · filed 2022-11-03
-$65.27M
derived: sum of 4 quarters · filed 2023-03-14
2021-06-30-$13.42M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
-$32.74M
10-Q · filed 2022-08-08
-$54.45M
derived: sum of 3 quarters · filed 2023-03-14
-$9.70M
derived: sum of 4 quarters · filed 2023-03-14
2021-03-31-$19.32M
10-Q · filed 2022-05-09
-$41.02M
derived: sum of 2 quarters · filed 2023-03-14
$3.73M
derived: sum of 3 quarters · filed 2023-03-14
-$18.82M
derived: sum of 4 quarters · filed 2023-03-14
2020-12-31-$21.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14
$23.04M
derived: sum of 2 quarters · filed 2023-03-14
$497.00K
derived: sum of 3 quarters · filed 2023-03-14
-$33.51M
10-K · filed 2023-03-14
2020-09-30$44.75M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
$22.20M
derived: sum of 2 quarters · filed 2021-11-04
-$11.80M
10-Q · filed 2021-11-04
-$49.02M
derived: sum of 4 quarters · filed 2022-03-28
2020-06-30-$22.55M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02
-$56.55M
10-Q · filed 2021-08-02
-$93.77M
derived: sum of 3 quarters · filed 2022-03-28
-$121.62M
derived: sum of 4 quarters · filed 2022-03-28
2020-03-31-$34.00M
10-Q · filed 2021-05-11
-$71.22M
derived: sum of 2 quarters · filed 2022-03-28
-$99.07M
derived: sum of 3 quarters · filed 2022-03-28
-$133.74M
derived: sum of 4 quarters · filed 2022-03-28
2019-12-31-$37.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28
-$65.07M
derived: sum of 2 quarters · filed 2022-03-28
-$99.74M
derived: sum of 3 quarters · filed 2022-03-28
-$138.52M
10-K · filed 2022-03-28
2019-09-30-$27.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
-$62.52M
derived: sum of 2 quarters · filed 2020-11-09
-$101.30M
10-Q · filed 2020-11-09
-$120.48M
derived: sum of 4 quarters · filed 2021-03-18
2019-06-30-$34.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
-$73.45M
10-Q · filed 2020-08-10
-$92.64M
derived: sum of 3 quarters · filed 2021-03-18
-$115.20M
derived: sum of 4 quarters · filed 2021-03-18
2019-03-31-$38.78M
10-Q · filed 2020-05-07
-$57.97M
derived: sum of 2 quarters · filed 2021-03-18
-$80.53M
derived: sum of 3 quarters · filed 2021-03-18
-$90.84M
derived: sum of 4 quarters · filed 2021-03-18
2018-12-31-$19.19M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18
-$41.75M
derived: sum of 2 quarters · filed 2021-03-18
-$52.06M
derived: sum of 3 quarters · filed 2021-03-18
-$74.52M
10-K · filed 2021-03-18
2018-09-30-$22.56M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30
-$32.87M
derived: sum of 2 quarters · filed 2019-10-30
-$55.33M
10-Q · filed 2019-10-30
-$75.65M
derived: sum of 4 quarters · filed 2020-03-11
2018-06-30-$10.31M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
-$32.77M
10-Q · filed 2019-08-01
-$53.09M
derived: sum of 3 quarters · filed 2020-03-11
-$64.94M
derived: sum of 4 quarters · filed 2020-03-11
2018-03-31-$22.45M
10-Q · filed 2019-05-09
-$42.78M
derived: sum of 2 quarters · filed 2020-03-11
-$54.63M
derived: sum of 3 quarters · filed 2020-03-11
-$69.11M
derived: sum of 4 quarters · filed 2020-03-11
2017-12-31-$20.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11
-$32.18M
derived: sum of 2 quarters · filed 2020-03-11
-$46.66M
derived: sum of 3 quarters · filed 2020-03-11
-$57.31M
10-K · filed 2020-03-11
2017-09-30-$11.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
-$26.33M
derived: sum of 2 quarters · filed 2018-11-07
-$36.98M
10-Q · filed 2018-11-07
-$42.94M
derived: sum of 4 quarters · filed 2019-03-12
2017-06-30-$14.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
-$25.13M
10-Q · filed 2018-08-08
-$31.09M
derived: sum of 3 quarters · filed 2019-03-12
-$37.10M
derived: sum of 4 quarters · filed 2019-03-12
2017-03-31-$10.65M
10-Q · filed 2018-05-03
-$16.60M
derived: sum of 2 quarters · filed 2019-03-12
-$22.62M
derived: sum of 3 quarters · filed 2019-03-12
2016-12-31-$5.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12
-$11.97M
derived: sum of 2 quarters · filed 2019-03-12
-$29.48M
10-K · filed 2019-03-12
2016-09-30-$6.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
-$23.53M
10-Q · filed 2017-11-07
2016-06-30-$17.51M
10-Q · filed 2017-08-08
2015-12-31-$45.56M
10-K · filed 2018-03-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
IRONWOOD PHARMACEUTICALS INC (IRWD)United States$0.694B5.37
Climb Bio, Inc. (CLYM)United States$0.683B-13.03
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Faeth Therapeutics, Inc. (FTH)United States$0.750B
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
Wave Life Sciences, Inc. (WVE)$0.780B-5.56